Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 59 NOK 0.51% Market Closed
Market Cap: 1.6B NOK
Have any thoughts about
Photocure ASA?
Write Note

Photocure ASA
Investor Relations

Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Mr. Daniel Schneider
President & CEO
No Bio Available
Mr. Erik Dahl
Chief Financial Officer
No Bio Available
Mr. David Moskowitz
Head of Investor Relations
No Bio Available
Anja Gossens-von der Heidt
Head of Global Human Resources
No Bio Available
Dr. Anders Neijber M.D.
Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D
No Bio Available
Mr. Tolv Hillestad
Group Controller
No Bio Available

Contacts

Address
OSLO
Oslo
Hoffsveien 4
Contacts
+4722062210.0
www.photocure.com